nodes	percent_of_prediction	percent_of_DWPC	metapath
L-DOPA—Mesalazine—Crohn's disease	0.59	1	CrCtD
L-DOPA—Aminosalicylic Acid—Mesalazine—Crohn's disease	0.0952	0.27	CrCrCtD
L-DOPA—Carbidopa—Mesalazine—Crohn's disease	0.0716	0.203	CrCrCtD
L-DOPA—Methyldopa—Mesalazine—Crohn's disease	0.0619	0.176	CrCrCtD
L-DOPA—Dopamine—Mesalazine—Crohn's disease	0.0619	0.176	CrCrCtD
L-DOPA—Droxidopa—Mesalazine—Crohn's disease	0.0619	0.176	CrCrCtD
L-DOPA—SLC7A5—Balsalazide—Sulfasalazine—Crohn's disease	0.00135	0.878	CbGdCrCtD
L-DOPA—SLC7A8—mouth—Crohn's disease	0.00132	0.104	CbGeAlD
L-DOPA—Urine color abnormal—Mesalazine—Crohn's disease	0.0012	0.0473	CcSEcCtD
L-DOPA—Malignant melanoma—Azathioprine—Crohn's disease	0.00119	0.0469	CcSEcCtD
L-DOPA—PSIP1—mammalian vulva—Crohn's disease	0.00101	0.0795	CbGeAlD
L-DOPA—PSIP1—lymphoid tissue—Crohn's disease	0.000898	0.0706	CbGeAlD
L-DOPA—PSIP1—digestive system—Crohn's disease	0.000887	0.0697	CbGeAlD
L-DOPA—Glossodynia—Mesalazine—Crohn's disease	0.000847	0.0334	CcSEcCtD
L-DOPA—Chromaturia—Mesalazine—Crohn's disease	0.000792	0.0312	CcSEcCtD
L-DOPA—SLC7A8—skin of body—Crohn's disease	0.000731	0.0574	CbGeAlD
L-DOPA—Bacterial infection—Azathioprine—Crohn's disease	0.000673	0.0265	CcSEcCtD
L-DOPA—SLC7A5—epithelium—Crohn's disease	0.000595	0.0468	CbGeAlD
L-DOPA—Duodenal ulcer—Mesalazine—Crohn's disease	0.000585	0.0231	CcSEcCtD
L-DOPA—SLC7A5—smooth muscle tissue—Crohn's disease	0.000574	0.0451	CbGeAlD
L-DOPA—SLC7A5—skin of body—Crohn's disease	0.000566	0.0445	CbGeAlD
L-DOPA—SLC7A5—mammalian vulva—Crohn's disease	0.000516	0.0406	CbGeAlD
L-DOPA—PSIP1—lymph node—Crohn's disease	0.000507	0.0398	CbGeAlD
L-DOPA—SLC15A1—epithelium—Crohn's disease	0.000494	0.0388	CbGeAlD
L-DOPA—DRD5—lymphoid tissue—Crohn's disease	0.000492	0.0387	CbGeAlD
L-DOPA—SLC7A5—lymphoid tissue—Crohn's disease	0.000459	0.036	CbGeAlD
L-DOPA—SLC16A10—epithelium—Crohn's disease	0.000456	0.0358	CbGeAlD
L-DOPA—SLC7A5—digestive system—Crohn's disease	0.000453	0.0356	CbGeAlD
L-DOPA—SLC15A1—mammalian vulva—Crohn's disease	0.000429	0.0337	CbGeAlD
L-DOPA—SLC16A10—mammalian vulva—Crohn's disease	0.000395	0.0311	CbGeAlD
L-DOPA—Blister—Mesalazine—Crohn's disease	0.000392	0.0155	CcSEcCtD
L-DOPA—SLC15A1—digestive system—Crohn's disease	0.000376	0.0295	CbGeAlD
L-DOPA—Dementia—Prednisone—Crohn's disease	0.000365	0.0144	CcSEcCtD
L-DOPA—Aminosalicylic Acid—MPO—Crohn's disease	0.000357	0.211	CrCbGaD
L-DOPA—SLC16A10—lymphoid tissue—Crohn's disease	0.000351	0.0276	CbGeAlD
L-DOPA—Blood disorder—Mesalazine—Crohn's disease	0.000339	0.0134	CcSEcCtD
L-DOPA—SLC7A8—lymph node—Crohn's disease	0.000334	0.0262	CbGeAlD
L-DOPA—DDC—lymph node—Crohn's disease	0.000289	0.0227	CbGeAlD
L-DOPA—Musculoskeletal pain—Mesalazine—Crohn's disease	0.000286	0.0113	CcSEcCtD
L-DOPA—Mesalazine—MPO—Crohn's disease	0.00028	0.166	CrCbGaD
L-DOPA—Blood urea increased—Mesalazine—Crohn's disease	0.000267	0.0105	CcSEcCtD
L-DOPA—SLC7A5—lymph node—Crohn's disease	0.000259	0.0203	CbGeAlD
L-DOPA—Alopecia—Mercaptopurine—Crohn's disease	0.000231	0.00912	CcSEcCtD
L-DOPA—Disorientation—Mesalazine—Crohn's disease	0.000229	0.00905	CcSEcCtD
L-DOPA—Dermatitis bullous—Mesalazine—Crohn's disease	0.000215	0.00847	CcSEcCtD
L-DOPA—Norepinephrine—SLC22A5—Crohn's disease	0.000214	0.127	CrCbGaD
L-DOPA—Delusion—Prednisone—Crohn's disease	0.000211	0.00834	CcSEcCtD
L-DOPA—Anaemia—Mercaptopurine—Crohn's disease	0.000211	0.0083	CcSEcCtD
L-DOPA—Mania—Prednisone—Crohn's disease	0.000206	0.00811	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Mesalazine—Crohn's disease	0.000205	0.0081	CcSEcCtD
L-DOPA—Leukopenia—Mercaptopurine—Crohn's disease	0.000204	0.00804	CcSEcCtD
L-DOPA—Disturbance in sexual arousal—Mesalazine—Crohn's disease	0.000204	0.00803	CcSEcCtD
L-DOPA—Dopamine—SLC22A5—Crohn's disease	0.000199	0.118	CrCbGaD
L-DOPA—SLC16A10—lymph node—Crohn's disease	0.000198	0.0156	CbGeAlD
L-DOPA—Epinephrine—SLC22A5—Crohn's disease	0.000194	0.115	CrCbGaD
L-DOPA—Blood creatinine increased—Mesalazine—Crohn's disease	0.000192	0.00758	CcSEcCtD
L-DOPA—Memory impairment—Prednisone—Crohn's disease	0.000191	0.00752	CcSEcCtD
L-DOPA—SLC7A5—Desoximetasone—Prednisone—Crohn's disease	0.000188	0.122	CbGdCrCtD
L-DOPA—Orthostatic hypotension—Mesalazine—Crohn's disease	0.000188	0.00739	CcSEcCtD
L-DOPA—Oedema—Mercaptopurine—Crohn's disease	0.000186	0.00733	CcSEcCtD
L-DOPA—Cramp muscle—Mesalazine—Crohn's disease	0.000185	0.00729	CcSEcCtD
L-DOPA—Nasopharyngitis—Mesalazine—Crohn's disease	0.000184	0.00724	CcSEcCtD
L-DOPA—Thrombocytopenia—Mercaptopurine—Crohn's disease	0.000182	0.00718	CcSEcCtD
L-DOPA—Gastritis—Mesalazine—Crohn's disease	0.000182	0.00716	CcSEcCtD
L-DOPA—Dysphagia—Mesalazine—Crohn's disease	0.000177	0.007	CcSEcCtD
L-DOPA—Anorexia—Mercaptopurine—Crohn's disease	0.000177	0.00699	CcSEcCtD
L-DOPA—Angina pectoris—Mesalazine—Crohn's disease	0.000173	0.00682	CcSEcCtD
L-DOPA—Upper respiratory tract infection—Mesalazine—Crohn's disease	0.000165	0.0065	CcSEcCtD
L-DOPA—Pollakiuria—Mesalazine—Crohn's disease	0.000164	0.00646	CcSEcCtD
L-DOPA—Agranulocytosis—Azathioprine—Crohn's disease	0.000162	0.00639	CcSEcCtD
L-DOPA—Decreased appetite—Mercaptopurine—Crohn's disease	0.000162	0.00637	CcSEcCtD
L-DOPA—Weight increased—Mesalazine—Crohn's disease	0.000161	0.00637	CcSEcCtD
L-DOPA—Weight decreased—Mesalazine—Crohn's disease	0.000161	0.00633	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Mercaptopurine—Crohn's disease	0.000161	0.00633	CcSEcCtD
L-DOPA—Depression—Mesalazine—Crohn's disease	0.000158	0.00622	CcSEcCtD
L-DOPA—Haemoglobin—Azathioprine—Crohn's disease	0.000157	0.00618	CcSEcCtD
L-DOPA—Haemorrhage—Azathioprine—Crohn's disease	0.000156	0.00615	CcSEcCtD
L-DOPA—Neuropathy peripheral—Mesalazine—Crohn's disease	0.000155	0.00611	CcSEcCtD
L-DOPA—Urinary tract infection—Mesalazine—Crohn's disease	0.000154	0.00606	CcSEcCtD
L-DOPA—Hiccups—Prednisone—Crohn's disease	0.00015	0.0059	CcSEcCtD
L-DOPA—Agranulocytosis—Mesalazine—Crohn's disease	0.000148	0.00582	CcSEcCtD
L-DOPA—Haemoglobin—Mesalazine—Crohn's disease	0.000143	0.00563	CcSEcCtD
L-DOPA—Rhinitis—Mesalazine—Crohn's disease	0.000142	0.00561	CcSEcCtD
L-DOPA—Haemorrhage—Mesalazine—Crohn's disease	0.000142	0.0056	CcSEcCtD
L-DOPA—Urinary tract disorder—Mesalazine—Crohn's disease	0.00014	0.00553	CcSEcCtD
L-DOPA—Arrhythmia—Azathioprine—Crohn's disease	0.000139	0.00549	CcSEcCtD
L-DOPA—Urethral disorder—Mesalazine—Crohn's disease	0.000139	0.00549	CcSEcCtD
L-DOPA—Alopecia—Azathioprine—Crohn's disease	0.000138	0.00543	CcSEcCtD
L-DOPA—Hypersensitivity—Mercaptopurine—Crohn's disease	0.000137	0.0054	CcSEcCtD
L-DOPA—Aminosalicylic Acid—PTGS2—Crohn's disease	0.000134	0.0791	CrCbGaD
L-DOPA—CYP2D6—digestive system—Crohn's disease	0.000132	0.0104	CbGeAlD
L-DOPA—Hyperkinesia—Prednisone—Crohn's disease	0.000131	0.00515	CcSEcCtD
L-DOPA—Euphoric mood—Prednisone—Crohn's disease	0.000129	0.00507	CcSEcCtD
L-DOPA—Epinephrine—TNF—Crohn's disease	0.000127	0.0753	CrCbGaD
L-DOPA—Diarrhoea—Mercaptopurine—Crohn's disease	0.000127	0.00502	CcSEcCtD
L-DOPA—Ill-defined disorder—Azathioprine—Crohn's disease	0.000126	0.00497	CcSEcCtD
L-DOPA—Alopecia—Mesalazine—Crohn's disease	0.000126	0.00495	CcSEcCtD
L-DOPA—Anaemia—Azathioprine—Crohn's disease	0.000125	0.00495	CcSEcCtD
L-DOPA—Mental disorder—Mesalazine—Crohn's disease	0.000124	0.00491	CcSEcCtD
L-DOPA—Malaise—Azathioprine—Crohn's disease	0.000122	0.00483	CcSEcCtD
L-DOPA—Flatulence—Mesalazine—Crohn's disease	0.000122	0.0048	CcSEcCtD
L-DOPA—Leukopenia—Azathioprine—Crohn's disease	0.000121	0.00479	CcSEcCtD
L-DOPA—Vascular purpura—Prednisone—Crohn's disease	0.000121	0.00479	CcSEcCtD
L-DOPA—Tension—Mesalazine—Crohn's disease	0.000121	0.00478	CcSEcCtD
L-DOPA—Dysgeusia—Mesalazine—Crohn's disease	0.000121	0.00477	CcSEcCtD
L-DOPA—Nervousness—Mesalazine—Crohn's disease	0.00012	0.00473	CcSEcCtD
L-DOPA—Back pain—Mesalazine—Crohn's disease	0.00012	0.00472	CcSEcCtD
L-DOPA—Muscle spasms—Mesalazine—Crohn's disease	0.000119	0.00469	CcSEcCtD
L-DOPA—Vomiting—Mercaptopurine—Crohn's disease	0.000118	0.00466	CcSEcCtD
L-DOPA—Rash—Mercaptopurine—Crohn's disease	0.000117	0.00462	CcSEcCtD
L-DOPA—Dermatitis—Mercaptopurine—Crohn's disease	0.000117	0.00462	CcSEcCtD
L-DOPA—Vision blurred—Mesalazine—Crohn's disease	0.000117	0.00459	CcSEcCtD
L-DOPA—Tremor—Mesalazine—Crohn's disease	0.000116	0.00457	CcSEcCtD
L-DOPA—Ill-defined disorder—Mesalazine—Crohn's disease	0.000115	0.00452	CcSEcCtD
L-DOPA—Anaemia—Mesalazine—Crohn's disease	0.000114	0.00451	CcSEcCtD
L-DOPA—Discomfort—Azathioprine—Crohn's disease	0.000114	0.0045	CcSEcCtD
L-DOPA—Angioedema—Mesalazine—Crohn's disease	0.000113	0.00445	CcSEcCtD
L-DOPA—Purpura—Prednisone—Crohn's disease	0.000113	0.00444	CcSEcCtD
L-DOPA—Malaise—Mesalazine—Crohn's disease	0.000111	0.0044	CcSEcCtD
L-DOPA—Syncope—Mesalazine—Crohn's disease	0.000111	0.00437	CcSEcCtD
L-DOPA—Leukopenia—Mesalazine—Crohn's disease	0.000111	0.00436	CcSEcCtD
L-DOPA—Nausea—Mercaptopurine—Crohn's disease	0.00011	0.00435	CcSEcCtD
L-DOPA—Palpitations—Mesalazine—Crohn's disease	0.000109	0.00431	CcSEcCtD
L-DOPA—Loss of consciousness—Mesalazine—Crohn's disease	0.000109	0.00428	CcSEcCtD
L-DOPA—Gastrointestinal haemorrhage—Prednisone—Crohn's disease	0.000109	0.00428	CcSEcCtD
L-DOPA—Thrombocytopenia—Azathioprine—Crohn's disease	0.000108	0.00428	CcSEcCtD
L-DOPA—Cough—Mesalazine—Crohn's disease	0.000108	0.00425	CcSEcCtD
L-DOPA—Hypertension—Mesalazine—Crohn's disease	0.000107	0.00421	CcSEcCtD
L-DOPA—Psychotic disorder—Prednisone—Crohn's disease	0.000106	0.00418	CcSEcCtD
L-DOPA—Chest pain—Mesalazine—Crohn's disease	0.000105	0.00415	CcSEcCtD
L-DOPA—Mesalazine—PTGS2—Crohn's disease	0.000105	0.0621	CrCbGaD
L-DOPA—Anxiety—Mesalazine—Crohn's disease	0.000105	0.00414	CcSEcCtD
L-DOPA—Discomfort—Mesalazine—Crohn's disease	0.000104	0.0041	CcSEcCtD
L-DOPA—Hypotension—Azathioprine—Crohn's disease	0.000104	0.00408	CcSEcCtD
L-DOPA—Dry mouth—Mesalazine—Crohn's disease	0.000103	0.00406	CcSEcCtD
L-DOPA—Confusional state—Mesalazine—Crohn's disease	0.000102	0.00401	CcSEcCtD
L-DOPA—Oedema—Mesalazine—Crohn's disease	0.000101	0.00398	CcSEcCtD
L-DOPA—Shock—Mesalazine—Crohn's disease	9.93e-05	0.00391	CcSEcCtD
L-DOPA—Thrombocytopenia—Mesalazine—Crohn's disease	9.88e-05	0.0039	CcSEcCtD
L-DOPA—Hyperhidrosis—Mesalazine—Crohn's disease	9.75e-05	0.00385	CcSEcCtD
L-DOPA—Anorexia—Mesalazine—Crohn's disease	9.62e-05	0.00379	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Azathioprine—Crohn's disease	9.56e-05	0.00377	CcSEcCtD
L-DOPA—Hypotension—Mesalazine—Crohn's disease	9.43e-05	0.00372	CcSEcCtD
L-DOPA—Sweating increased—Prednisone—Crohn's disease	9.14e-05	0.00361	CcSEcCtD
L-DOPA—Feeling abnormal—Azathioprine—Crohn's disease	9.13e-05	0.0036	CcSEcCtD
L-DOPA—Insomnia—Mesalazine—Crohn's disease	9.13e-05	0.0036	CcSEcCtD
L-DOPA—Paraesthesia—Mesalazine—Crohn's disease	9.06e-05	0.00357	CcSEcCtD
L-DOPA—Gastrointestinal pain—Azathioprine—Crohn's disease	9.06e-05	0.00357	CcSEcCtD
L-DOPA—Dyspnoea—Mesalazine—Crohn's disease	9e-05	0.00355	CcSEcCtD
L-DOPA—Somnolence—Mesalazine—Crohn's disease	8.97e-05	0.00354	CcSEcCtD
L-DOPA—Dyspepsia—Mesalazine—Crohn's disease	8.88e-05	0.0035	CcSEcCtD
L-DOPA—Decreased appetite—Mesalazine—Crohn's disease	8.77e-05	0.00346	CcSEcCtD
L-DOPA—Abdominal pain—Azathioprine—Crohn's disease	8.76e-05	0.00345	CcSEcCtD
L-DOPA—Gastrointestinal disorder—Mesalazine—Crohn's disease	8.71e-05	0.00343	CcSEcCtD
L-DOPA—Fatigue—Mesalazine—Crohn's disease	8.7e-05	0.00343	CcSEcCtD
L-DOPA—Constipation—Mesalazine—Crohn's disease	8.63e-05	0.0034	CcSEcCtD
L-DOPA—Pain—Mesalazine—Crohn's disease	8.63e-05	0.0034	CcSEcCtD
L-DOPA—Weight increased—Prednisone—Crohn's disease	8.54e-05	0.00337	CcSEcCtD
L-DOPA—Weight decreased—Prednisone—Crohn's disease	8.49e-05	0.00335	CcSEcCtD
L-DOPA—Depression—Prednisone—Crohn's disease	8.35e-05	0.00329	CcSEcCtD
L-DOPA—Feeling abnormal—Mesalazine—Crohn's disease	8.32e-05	0.00328	CcSEcCtD
L-DOPA—Acute coronary syndrome—Prednisone—Crohn's disease	8.25e-05	0.00325	CcSEcCtD
L-DOPA—Gastrointestinal pain—Mesalazine—Crohn's disease	8.25e-05	0.00325	CcSEcCtD
L-DOPA—Neuropathy peripheral—Prednisone—Crohn's disease	8.21e-05	0.00324	CcSEcCtD
L-DOPA—Myocardial infarction—Prednisone—Crohn's disease	8.21e-05	0.00324	CcSEcCtD
L-DOPA—Hypersensitivity—Azathioprine—Crohn's disease	8.16e-05	0.00322	CcSEcCtD
L-DOPA—Liothyronine—ALB—Crohn's disease	8.06e-05	0.0476	CrCbGaD
L-DOPA—Urticaria—Mesalazine—Crohn's disease	8.02e-05	0.00316	CcSEcCtD
L-DOPA—Abdominal pain—Mesalazine—Crohn's disease	7.98e-05	0.00315	CcSEcCtD
L-DOPA—Diarrhoea—Azathioprine—Crohn's disease	7.58e-05	0.00299	CcSEcCtD
L-DOPA—Haemoglobin—Prednisone—Crohn's disease	7.55e-05	0.00298	CcSEcCtD
L-DOPA—Haemorrhage—Prednisone—Crohn's disease	7.51e-05	0.00296	CcSEcCtD
L-DOPA—Hallucination—Prednisone—Crohn's disease	7.48e-05	0.00295	CcSEcCtD
L-DOPA—Hypersensitivity—Mesalazine—Crohn's disease	7.43e-05	0.00293	CcSEcCtD
L-DOPA—Dizziness—Azathioprine—Crohn's disease	7.33e-05	0.00289	CcSEcCtD
L-DOPA—Asthenia—Mesalazine—Crohn's disease	7.24e-05	0.00285	CcSEcCtD
L-DOPA—Pruritus—Mesalazine—Crohn's disease	7.14e-05	0.00281	CcSEcCtD
L-DOPA—Vomiting—Azathioprine—Crohn's disease	7.04e-05	0.00278	CcSEcCtD
L-DOPA—Rash—Azathioprine—Crohn's disease	6.98e-05	0.00275	CcSEcCtD
L-DOPA—Dermatitis—Azathioprine—Crohn's disease	6.98e-05	0.00275	CcSEcCtD
L-DOPA—Flushing—Prednisone—Crohn's disease	6.97e-05	0.00275	CcSEcCtD
L-DOPA—Headache—Azathioprine—Crohn's disease	6.94e-05	0.00274	CcSEcCtD
L-DOPA—Diarrhoea—Mesalazine—Crohn's disease	6.9e-05	0.00272	CcSEcCtD
L-DOPA—Arrhythmia—Prednisone—Crohn's disease	6.71e-05	0.00265	CcSEcCtD
L-DOPA—Dizziness—Mesalazine—Crohn's disease	6.67e-05	0.00263	CcSEcCtD
L-DOPA—Alopecia—Prednisone—Crohn's disease	6.64e-05	0.00262	CcSEcCtD
L-DOPA—Mental disorder—Prednisone—Crohn's disease	6.58e-05	0.0026	CcSEcCtD
L-DOPA—Nausea—Azathioprine—Crohn's disease	6.58e-05	0.00259	CcSEcCtD
L-DOPA—Vomiting—Mesalazine—Crohn's disease	6.42e-05	0.00253	CcSEcCtD
L-DOPA—Rash—Mesalazine—Crohn's disease	6.36e-05	0.00251	CcSEcCtD
L-DOPA—Dermatitis—Mesalazine—Crohn's disease	6.36e-05	0.00251	CcSEcCtD
L-DOPA—Headache—Mesalazine—Crohn's disease	6.32e-05	0.00249	CcSEcCtD
L-DOPA—Vision blurred—Prednisone—Crohn's disease	6.16e-05	0.00243	CcSEcCtD
L-DOPA—Ill-defined disorder—Prednisone—Crohn's disease	6.07e-05	0.00239	CcSEcCtD
L-DOPA—Anaemia—Prednisone—Crohn's disease	6.05e-05	0.00238	CcSEcCtD
L-DOPA—Agitation—Prednisone—Crohn's disease	6.01e-05	0.00237	CcSEcCtD
L-DOPA—Nausea—Mesalazine—Crohn's disease	5.99e-05	0.00236	CcSEcCtD
L-DOPA—Angioedema—Prednisone—Crohn's disease	5.98e-05	0.00236	CcSEcCtD
L-DOPA—Malaise—Prednisone—Crohn's disease	5.9e-05	0.00233	CcSEcCtD
L-DOPA—Syncope—Prednisone—Crohn's disease	5.87e-05	0.00231	CcSEcCtD
L-DOPA—Loss of consciousness—Prednisone—Crohn's disease	5.75e-05	0.00227	CcSEcCtD
L-DOPA—Convulsion—Prednisone—Crohn's disease	5.67e-05	0.00223	CcSEcCtD
L-DOPA—Hypertension—Prednisone—Crohn's disease	5.65e-05	0.00223	CcSEcCtD
L-DOPA—Anxiety—Prednisone—Crohn's disease	5.55e-05	0.00219	CcSEcCtD
L-DOPA—Discomfort—Prednisone—Crohn's disease	5.5e-05	0.00217	CcSEcCtD
L-DOPA—Oedema—Prednisone—Crohn's disease	5.34e-05	0.00211	CcSEcCtD
L-DOPA—Shock—Prednisone—Crohn's disease	5.25e-05	0.00207	CcSEcCtD
L-DOPA—Hyperhidrosis—Prednisone—Crohn's disease	5.16e-05	0.00204	CcSEcCtD
L-DOPA—Anorexia—Prednisone—Crohn's disease	5.09e-05	0.00201	CcSEcCtD
L-DOPA—Insomnia—Prednisone—Crohn's disease	4.83e-05	0.0019	CcSEcCtD
L-DOPA—Paraesthesia—Prednisone—Crohn's disease	4.79e-05	0.00189	CcSEcCtD
L-DOPA—Dyspepsia—Prednisone—Crohn's disease	4.7e-05	0.00185	CcSEcCtD
L-DOPA—Decreased appetite—Prednisone—Crohn's disease	4.64e-05	0.00183	CcSEcCtD
L-DOPA—Fatigue—Prednisone—Crohn's disease	4.6e-05	0.00181	CcSEcCtD
L-DOPA—Constipation—Prednisone—Crohn's disease	4.57e-05	0.0018	CcSEcCtD
L-DOPA—Feeling abnormal—Prednisone—Crohn's disease	4.4e-05	0.00173	CcSEcCtD
L-DOPA—Gastrointestinal pain—Prednisone—Crohn's disease	4.37e-05	0.00172	CcSEcCtD
L-DOPA—Urticaria—Prednisone—Crohn's disease	4.24e-05	0.00167	CcSEcCtD
L-DOPA—Abdominal pain—Prednisone—Crohn's disease	4.22e-05	0.00166	CcSEcCtD
L-DOPA—Hypersensitivity—Prednisone—Crohn's disease	3.93e-05	0.00155	CcSEcCtD
L-DOPA—Asthenia—Prednisone—Crohn's disease	3.83e-05	0.00151	CcSEcCtD
L-DOPA—Pruritus—Prednisone—Crohn's disease	3.78e-05	0.00149	CcSEcCtD
L-DOPA—Diarrhoea—Prednisone—Crohn's disease	3.65e-05	0.00144	CcSEcCtD
L-DOPA—Dizziness—Prednisone—Crohn's disease	3.53e-05	0.00139	CcSEcCtD
L-DOPA—Vomiting—Prednisone—Crohn's disease	3.39e-05	0.00134	CcSEcCtD
L-DOPA—Rash—Prednisone—Crohn's disease	3.37e-05	0.00133	CcSEcCtD
L-DOPA—Dermatitis—Prednisone—Crohn's disease	3.36e-05	0.00133	CcSEcCtD
L-DOPA—Headache—Prednisone—Crohn's disease	3.34e-05	0.00132	CcSEcCtD
L-DOPA—Nausea—Prednisone—Crohn's disease	3.17e-05	0.00125	CcSEcCtD
L-DOPA—DRD2—Signaling by GPCR—ACKR2—Crohn's disease	2.27e-05	0.00139	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—GPR65—Crohn's disease	2.24e-05	0.00138	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—PTGER4—Crohn's disease	2.24e-05	0.00138	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—Crohn's disease	2.22e-05	0.00137	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—PTGER4—Crohn's disease	2.21e-05	0.00136	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCR9—Crohn's disease	2.19e-05	0.00135	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GPX4—Crohn's disease	2.19e-05	0.00134	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCR9—Crohn's disease	2.17e-05	0.00134	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CCR6—Crohn's disease	2.17e-05	0.00133	CbGpPWpGaD
L-DOPA—SLC7A5—Hemostasis—JAK2—Crohn's disease	2.15e-05	0.00132	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—MLN—Crohn's disease	2.15e-05	0.00132	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCR9—Crohn's disease	2.14e-05	0.00132	CbGpPWpGaD
L-DOPA—DDC—Metabolism—GCKR—Crohn's disease	2.11e-05	0.0013	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—GPR65—Crohn's disease	2.04e-05	0.00125	CbGpPWpGaD
L-DOPA—SLC15A1—SLC-mediated transmembrane transport—ALB—Crohn's disease	2.04e-05	0.00125	CbGpPWpGaD
L-DOPA—DDC—SIDS Susceptibility Pathways—IL6—Crohn's disease	2.02e-05	0.00124	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RSPO3—Crohn's disease	2.02e-05	0.00124	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—GPR65—Crohn's disease	2.02e-05	0.00124	CbGpPWpGaD
L-DOPA—SLC7A5—Transmembrane transport of small molecules—ALB—Crohn's disease	2.01e-05	0.00123	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—GPR65—Crohn's disease	1.99e-05	0.00122	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCR9—Crohn's disease	1.97e-05	0.00121	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—ACKR2—Crohn's disease	1.97e-05	0.00121	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CCR6—Crohn's disease	1.97e-05	0.00121	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR9—Crohn's disease	1.95e-05	0.0012	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CCR6—Crohn's disease	1.92e-05	0.00118	CbGpPWpGaD
L-DOPA—PSIP1—Disease—TYK2—Crohn's disease	1.92e-05	0.00118	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SEL1L—Crohn's disease	1.92e-05	0.00118	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—PTGER4—Crohn's disease	1.91e-05	0.00117	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—MLN—Crohn's disease	1.87e-05	0.00115	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—GPR65—Crohn's disease	1.84e-05	0.00113	CbGpPWpGaD
L-DOPA—PSIP1—Disease—JAK2—Crohn's disease	1.83e-05	0.00113	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—GPR65—Crohn's disease	1.81e-05	0.00111	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—ACKR2—Crohn's disease	1.77e-05	0.00109	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR9—Crohn's disease	1.75e-05	0.00108	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—ACKR2—Crohn's disease	1.75e-05	0.00108	CbGpPWpGaD
L-DOPA—PSIP1—Disease—CD4—Crohn's disease	1.74e-05	0.00107	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—PTGER4—Crohn's disease	1.73e-05	0.00106	CbGpPWpGaD
L-DOPA—PSIP1—Disease—PTGS2—Crohn's disease	1.72e-05	0.00106	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TAGAP—Crohn's disease	1.71e-05	0.00105	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—PTGER4—Crohn's disease	1.69e-05	0.00104	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—MLN—Crohn's disease	1.68e-05	0.00103	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—MLN—Crohn's disease	1.66e-05	0.00102	CbGpPWpGaD
L-DOPA—DDC—Circadian rythm related genes—IL6—Crohn's disease	1.65e-05	0.00102	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR9—Crohn's disease	1.64e-05	0.00101	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—GPR65—Crohn's disease	1.63e-05	0.001	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL3—Crohn's disease	1.63e-05	0.000998	CbGpPWpGaD
L-DOPA—DRD5—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.62e-05	0.000997	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CCR6—Crohn's disease	1.6e-05	0.000983	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—RASGRP1—Crohn's disease	1.57e-05	0.000966	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TAGAP—Crohn's disease	1.54e-05	0.000945	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—GPR65—Crohn's disease	1.53e-05	0.000937	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TAGAP—Crohn's disease	1.52e-05	0.000933	CbGpPWpGaD
L-DOPA—DRD4—G alpha (i) signalling events—CXCL8—Crohn's disease	1.51e-05	0.000925	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RSPO3—Crohn's disease	1.49e-05	0.000918	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR9—Crohn's disease	1.49e-05	0.000916	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL3—Crohn's disease	1.48e-05	0.000907	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CCR6—Crohn's disease	1.45e-05	0.000892	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CCR6—Crohn's disease	1.44e-05	0.000885	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—RASGRP1—Crohn's disease	1.43e-05	0.000877	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CCR6—Crohn's disease	1.42e-05	0.000873	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SEL1L—Crohn's disease	1.42e-05	0.00087	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—PTGER4—Crohn's disease	1.41e-05	0.000865	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—GPR65—Crohn's disease	1.39e-05	0.000851	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RSPO3—Crohn's disease	1.34e-05	0.000826	CbGpPWpGaD
L-DOPA—PSIP1—Disease—STAT3—Crohn's disease	1.34e-05	0.000826	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—ACKR2—Crohn's disease	1.34e-05	0.000823	CbGpPWpGaD
L-DOPA—DRD3—G alpha (i) signalling events—CXCL8—Crohn's disease	1.34e-05	0.000822	CbGpPWpGaD
L-DOPA—SLC16A10—Transmembrane transport of small molecules—ALB—Crohn's disease	1.33e-05	0.000819	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RSPO3—Crohn's disease	1.33e-05	0.000815	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CCR6—Crohn's disease	1.31e-05	0.000803	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR9—Crohn's disease	1.3e-05	0.000796	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CCR6—Crohn's disease	1.29e-05	0.000793	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—PTGER4—Crohn's disease	1.28e-05	0.000786	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SEL1L—Crohn's disease	1.27e-05	0.000783	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—MLN—Crohn's disease	1.27e-05	0.00078	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—PTGER4—Crohn's disease	1.27e-05	0.000779	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SEL1L—Crohn's disease	1.26e-05	0.000773	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—PTGER4—Crohn's disease	1.25e-05	0.000768	CbGpPWpGaD
L-DOPA—DRD5—GPCR ligand binding—CXCL8—Crohn's disease	1.24e-05	0.000759	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—GPR65—Crohn's disease	1.2e-05	0.00074	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL3—Crohn's disease	1.2e-05	0.000737	CbGpPWpGaD
L-DOPA—DRD4—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.2e-05	0.000736	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR9—Crohn's disease	1.17e-05	0.000716	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CCR6—Crohn's disease	1.16e-05	0.000714	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TAGAP—Crohn's disease	1.16e-05	0.000714	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—RASGRP1—Crohn's disease	1.16e-05	0.000713	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—PTGER4—Crohn's disease	1.15e-05	0.000707	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR9—Crohn's disease	1.15e-05	0.000707	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—IL2RA—Crohn's disease	1.14e-05	0.000699	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—PTGER4—Crohn's disease	1.14e-05	0.000698	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL3—Crohn's disease	1.09e-05	0.000669	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CCR6—Crohn's disease	1.09e-05	0.000668	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—GPR65—Crohn's disease	1.08e-05	0.000666	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL3—Crohn's disease	1.08e-05	0.000663	CbGpPWpGaD
L-DOPA—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.08e-05	0.000662	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—GPR65—Crohn's disease	1.07e-05	0.000657	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL3—Crohn's disease	1.07e-05	0.000654	CbGpPWpGaD
L-DOPA—DRD3—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	1.06e-05	0.000654	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—RASGRP1—Crohn's disease	1.05e-05	0.000647	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RBX1—Crohn's disease	1.05e-05	0.000646	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—RASGRP1—Crohn's disease	1.04e-05	0.000642	CbGpPWpGaD
L-DOPA—SLC15A1—Transmembrane transport of small molecules—ALB—Crohn's disease	1.04e-05	0.000636	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL2RA—Crohn's disease	1.03e-05	0.000635	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—RASGRP1—Crohn's disease	1.03e-05	0.000633	CbGpPWpGaD
L-DOPA—DRD2—G alpha (i) signalling events—CXCL8—Crohn's disease	1.02e-05	0.000629	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—PTGER4—Crohn's disease	1.02e-05	0.000629	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RSPO3—Crohn's disease	1.02e-05	0.000624	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CCR6—Crohn's disease	9.87e-06	0.000606	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL3—Crohn's disease	9.81e-06	0.000602	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL3—Crohn's disease	9.67e-06	0.000594	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SEL1L—Crohn's disease	9.63e-06	0.000591	CbGpPWpGaD
L-DOPA—DRD4—Circadian rythm related genes—IL6—Crohn's disease	9.59e-06	0.000589	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—PTGER4—Crohn's disease	9.57e-06	0.000588	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—RASGRP1—Crohn's disease	9.48e-06	0.000583	CbGpPWpGaD
L-DOPA—PSIP1—Disease—IL6—Crohn's disease	9.39e-06	0.000577	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—RASGRP1—Crohn's disease	9.36e-06	0.000575	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—UBE2D1—Crohn's disease	9.22e-06	0.000566	CbGpPWpGaD
L-DOPA—DRD4—GPCR ligand binding—CXCL8—Crohn's disease	9.12e-06	0.00056	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RIPK2—Crohn's disease	8.94e-06	0.000549	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR9—Crohn's disease	8.8e-06	0.000541	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL3—Crohn's disease	8.72e-06	0.000536	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—PTGER4—Crohn's disease	8.69e-06	0.000534	CbGpPWpGaD
L-DOPA—DRD1—Circadian rythm related genes—IL6—Crohn's disease	8.63e-06	0.00053	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CCR6—Crohn's disease	8.58e-06	0.000527	CbGpPWpGaD
L-DOPA—DRD3—Circadian rythm related genes—IL6—Crohn's disease	8.52e-06	0.000523	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—RASGRP1—Crohn's disease	8.43e-06	0.000518	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—IL2RA—Crohn's disease	8.4e-06	0.000516	CbGpPWpGaD
L-DOPA—DRD1—GPCR ligand binding—CXCL8—Crohn's disease	8.21e-06	0.000504	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—GPR65—Crohn's disease	8.18e-06	0.000503	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL3—Crohn's disease	8.15e-06	0.000501	CbGpPWpGaD
L-DOPA—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—Crohn's disease	8.14e-06	0.0005	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PLA2G4F—Crohn's disease	8.1e-06	0.000498	CbGpPWpGaD
L-DOPA—DRD3—GPCR ligand binding—CXCL8—Crohn's disease	8.1e-06	0.000498	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—RASGRP1—Crohn's disease	7.88e-06	0.000484	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RBX1—Crohn's disease	7.76e-06	0.000477	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CCR6—Crohn's disease	7.72e-06	0.000475	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—JAK2—Crohn's disease	7.65e-06	0.00047	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SOCS1—Crohn's disease	7.64e-06	0.000469	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL2RA—Crohn's disease	7.63e-06	0.000469	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CCR6—Crohn's disease	7.62e-06	0.000468	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—IL2RA—Crohn's disease	7.56e-06	0.000465	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—PTGER4—Crohn's disease	7.55e-06	0.000464	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—IL2RA—Crohn's disease	7.46e-06	0.000458	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL3—Crohn's disease	7.4e-06	0.000455	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—TYK2—Crohn's disease	7.28e-06	0.000447	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—RASGRP1—Crohn's disease	7.16e-06	0.00044	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RBX1—Crohn's disease	6.99e-06	0.000429	CbGpPWpGaD
L-DOPA—DRD5—GPCR downstream signaling—CXCL8—Crohn's disease	6.98e-06	0.000429	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—JAK2—Crohn's disease	6.95e-06	0.000427	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RBX1—Crohn's disease	6.89e-06	0.000423	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—MTMR3—Crohn's disease	6.89e-06	0.000423	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL2RA—Crohn's disease	6.87e-06	0.000422	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—UBE2D1—Crohn's disease	6.8e-06	0.000418	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—PTGER4—Crohn's disease	6.8e-06	0.000418	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL2RA—Crohn's disease	6.78e-06	0.000416	CbGpPWpGaD
L-DOPA—DDC—Metabolism—ALB—Crohn's disease	6.72e-06	0.000413	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—PTGER4—Crohn's disease	6.71e-06	0.000412	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RIPK2—Crohn's disease	6.6e-06	0.000405	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—SMAD3—Crohn's disease	6.6e-06	0.000405	CbGpPWpGaD
L-DOPA—DRD2—Circadian rythm related genes—IL6—Crohn's disease	6.52e-06	0.0004	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL3—Crohn's disease	6.43e-06	0.000395	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—CXCL8—Crohn's disease	6.34e-06	0.00039	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—RASGRP1—Crohn's disease	6.22e-06	0.000382	CbGpPWpGaD
L-DOPA—DRD2—GPCR ligand binding—CXCL8—Crohn's disease	6.2e-06	0.000381	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—UBE2D1—Crohn's disease	6.13e-06	0.000376	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL2RA—Crohn's disease	6.11e-06	0.000375	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—UBE2D1—Crohn's disease	6.04e-06	0.000371	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RIPK2—Crohn's disease	5.94e-06	0.000365	CbGpPWpGaD
L-DOPA—DDC—Metabolism—PTGS2—Crohn's disease	5.88e-06	0.000361	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RIPK2—Crohn's disease	5.86e-06	0.00036	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CCR6—Crohn's disease	5.83e-06	0.000358	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL3—Crohn's disease	5.79e-06	0.000356	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL3—Crohn's disease	5.72e-06	0.000351	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—IL2RA—Crohn's disease	5.71e-06	0.000351	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—JAK2—Crohn's disease	5.65e-06	0.000347	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SOCS1—Crohn's disease	5.64e-06	0.000346	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—RASGRP1—Crohn's disease	5.6e-06	0.000344	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—RASGRP1—Crohn's disease	5.53e-06	0.00034	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—TYK2—Crohn's disease	5.38e-06	0.00033	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—FADS1—Crohn's disease	5.37e-06	0.00033	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RBX1—Crohn's disease	5.27e-06	0.000324	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL2RA—Crohn's disease	5.19e-06	0.000319	CbGpPWpGaD
L-DOPA—DRD4—GPCR downstream signaling—CXCL8—Crohn's disease	5.15e-06	0.000317	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—PTGER4—Crohn's disease	5.13e-06	0.000315	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—JAK2—Crohn's disease	5.13e-06	0.000315	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—JAK2—Crohn's disease	5.08e-06	0.000312	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SOCS1—Crohn's disease	5.08e-06	0.000312	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GPX4—Crohn's disease	5.03e-06	0.000309	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—JAK2—Crohn's disease	5.02e-06	0.000308	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SOCS1—Crohn's disease	5.01e-06	0.000308	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—SMAD3—Crohn's disease	4.87e-06	0.000299	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—GCKR—Crohn's disease	4.85e-06	0.000298	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—TYK2—Crohn's disease	4.84e-06	0.000297	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—TYK2—Crohn's disease	4.77e-06	0.000293	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—CXCL8—Crohn's disease	4.68e-06	0.000288	CbGpPWpGaD
L-DOPA—DRD1—GPCR downstream signaling—CXCL8—Crohn's disease	4.64e-06	0.000285	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—UBE2D1—Crohn's disease	4.62e-06	0.000284	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—JAK2—Crohn's disease	4.62e-06	0.000284	CbGpPWpGaD
L-DOPA—DRD3—GPCR downstream signaling—CXCL8—Crohn's disease	4.58e-06	0.000281	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—JAK2—Crohn's disease	4.56e-06	0.00028	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL2RA—Crohn's disease	4.51e-06	0.000277	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RIPK2—Crohn's disease	4.48e-06	0.000275	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—SMAD3—Crohn's disease	4.38e-06	0.000269	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL3—Crohn's disease	4.37e-06	0.000269	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—SMAD3—Crohn's disease	4.32e-06	0.000266	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—TYK2—Crohn's disease	4.3e-06	0.000264	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—RASGRP1—Crohn's disease	4.23e-06	0.00026	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—CXCL8—Crohn's disease	4.21e-06	0.000259	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—CXCL8—Crohn's disease	4.16e-06	0.000255	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—JAK2—Crohn's disease	4.1e-06	0.000252	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL2RA—Crohn's disease	4.06e-06	0.000249	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL2RA—Crohn's disease	4e-06	0.000246	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—JAK2—Crohn's disease	3.84e-06	0.000236	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SOCS1—Crohn's disease	3.83e-06	0.000235	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—CXCL8—Crohn's disease	3.75e-06	0.00023	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—TYK2—Crohn's disease	3.65e-06	0.000224	CbGpPWpGaD
L-DOPA—DRD5—Signaling by GPCR—IL6—Crohn's disease	3.56e-06	0.000219	CbGpPWpGaD
L-DOPA—DRD2—GPCR downstream signaling—CXCL8—Crohn's disease	3.5e-06	0.000215	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—JAK2—Crohn's disease	3.49e-06	0.000214	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—SMAD3—Crohn's disease	3.31e-06	0.000203	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—CXCL8—Crohn's disease	3.18e-06	0.000195	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—TYK2—Crohn's disease	3.18e-06	0.000195	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL2RA—Crohn's disease	3.06e-06	0.000188	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—JAK2—Crohn's disease	3.03e-06	0.000186	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—STAT3—Crohn's disease	3.01e-06	0.000185	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—TYK2—Crohn's disease	2.86e-06	0.000176	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—TYK2—Crohn's disease	2.82e-06	0.000173	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—CXCL8—Crohn's disease	2.76e-06	0.00017	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—JAK2—Crohn's disease	2.73e-06	0.000168	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—JAK2—Crohn's disease	2.69e-06	0.000165	CbGpPWpGaD
L-DOPA—DRD4—Signaling by GPCR—IL6—Crohn's disease	2.63e-06	0.000162	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—CXCL8—Crohn's disease	2.49e-06	0.000153	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—CXCL8—Crohn's disease	2.46e-06	0.000151	CbGpPWpGaD
L-DOPA—DRD1—Signaling by GPCR—IL6—Crohn's disease	2.37e-06	0.000145	CbGpPWpGaD
L-DOPA—DRD3—Signaling by GPCR—IL6—Crohn's disease	2.34e-06	0.000143	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—STAT3—Crohn's disease	2.22e-06	0.000137	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—TYK2—Crohn's disease	2.16e-06	0.000133	CbGpPWpGaD
L-DOPA—DRD5—Signaling Pathways—IL6—Crohn's disease	2.1e-06	0.000129	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—JAK2—Crohn's disease	2.06e-06	0.000126	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—STAT3—Crohn's disease	2e-06	0.000123	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—STAT3—Crohn's disease	1.98e-06	0.000121	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—CXCL8—Crohn's disease	1.88e-06	0.000115	CbGpPWpGaD
L-DOPA—DRD2—Signaling by GPCR—IL6—Crohn's disease	1.79e-06	0.00011	CbGpPWpGaD
L-DOPA—DRD4—Signaling Pathways—IL6—Crohn's disease	1.55e-06	9.54e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—ALB—Crohn's disease	1.55e-06	9.49e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—STAT3—Crohn's disease	1.51e-06	9.28e-05	CbGpPWpGaD
L-DOPA—DRD1—Signaling Pathways—IL6—Crohn's disease	1.4e-06	8.59e-05	CbGpPWpGaD
L-DOPA—DRD3—Signaling Pathways—IL6—Crohn's disease	1.38e-06	8.47e-05	CbGpPWpGaD
L-DOPA—CYP2D6—Metabolism—PTGS2—Crohn's disease	1.35e-06	8.3e-05	CbGpPWpGaD
L-DOPA—DRD2—Signaling Pathways—IL6—Crohn's disease	1.06e-06	6.48e-05	CbGpPWpGaD
